search
Back to results

Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia

Primary Purpose

Primary Insomnia

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Portable Biofeedback
Sponsored by
Helicor
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Insomnia focused on measuring Primary Insomnia, Chronic Insomnia, Biofeedback, Sleeplessness

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Between the ages of 18-55
  2. Met DSM-IV-TR criteria for Primary Insomnia as measured by the:

    • Structured Interview for Sleep Disorders.
    • Insomnia Severity Index (>14).
  3. Demonstrate Sleep Onset Latency of >=45 minutes on >= 3 nights per week greater than or equal to 6 days over the 2 week period.
  4. A mean SOL >= 30 minutes over the 2 week period between Screening and Baseline visits.
  5. Residential stability (1 year) and means to travel to appointments.
  6. Willing to provide the name and contact information of a secondary contact person.
  7. Off insomnia medications for at least one week prior to randomization and no more than 2 days of use during the first week of baseline.
  8. Ability to read in English.
  9. Provision of informed consent.
  10. Willing to comply with daily protocol.
  11. Ability to obtain a reading on the device.

Exclusion Criteria:

  1. Been in more than 2 studies in the past 2 years
  2. Pregnant
  3. Terminal, progressive, and or unstable medical illness.
  4. Self-reported sleep disruptive medical disorder i. Chronic Pain, Fibromyalgia, Pheochromocytoma, Hyperthyroidism, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes.
  5. Current Axis I psychiatric disorder.(DSM-IV) i. Major Depressive Disorder, Depression, Generalized Anxiety Disorder, Attention Deficit Disorder, Post Traumatic Stress Disorder, Bipolar Disorder, Substance/Alcohol Use Disorders, Attention Deficit Hyperactivity Disorder, Schizophrenia/Psychotic Disorders, Delirium, Dementia, and/or Amnesic disorders, Panic Disorder w/ nocturnal panic attacks.
  6. Chronic alcohol use not diagnosed in criterion 6. i. Subjects unwilling to limit their alcohol intake to 2 standard drinks per day will be excluded.
  7. Raynaud's Disease
  8. Regularly taking anti-anxiety medications, beta blockers or other heart medications that regulate heartbeat, bronchodilators, respiratory stimulants, simulating antidepressants, sedating antidepressants, thyroid supplements, anti-psychotics, and/or steroids.
  9. Regularly taking antidepressants (Prozac, Zoloft, Paxil) and NOT on a fixed dosage for at least 1 month prior to entering the study.
  10. Regularly taking medication (prescribed or over the counter) for sleep difficulties (>3x week). Sleep medications include any substance for sleep not limited to but including FDA approved sleep medications, analgesics, antihistamines, decongestants, melatonin, L-trypotophan, and velarian.
  11. Unwilling to abstain from PRN sleep aides (prescribed or over the counter).
  12. Restless Leg Syndrome as assessed by structured interview.
  13. Symptoms of Sleep Apnea (BMI>32 and Epworth Sleepiness Scale >10)
  14. Own a negative air ionizer or have used one in the past to treat insomnia.
  15. If subject recognizes device during the ability to obtain a pulse rate wave reading on the device.
  16. More than 5 cups (8oz) of caffeinated drinks per day and/or unwilling to limit caffeine in-take to a maximum of 3 cups a day and not after 5pm during the intervention.
  17. Regular night-time shift work and rotating night-time shift work.
  18. Idiopathic Insomnia.

Sites / Locations

  • Duke University Medical CenterRecruiting

Outcomes

Primary Outcome Measures

Sleep latency at 4 week follow-up

Secondary Outcome Measures

wake time after sleep onset (WASO) at 4 week follow-up
total awake time (SOL + WASO) at 4 week follow-up
Shifting from moderate/severe insomnia to mild/no insomnia (Insomnia Severity Index)at 4 week follow-up
Daytime functioning at 4 week follow-up

Full Information

First Posted
December 21, 2006
Last Updated
January 26, 2007
Sponsor
Helicor
search

1. Study Identification

Unique Protocol Identification Number
NCT00415714
Brief Title
Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
Official Title
A Randomized Controlled Pilot Trial Testing the Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2006
Overall Recruitment Status
Unknown status
Study Start Date
September 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2007 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Helicor

4. Oversight

5. Study Description

Brief Summary
The objective of this study is to determine the efficacy of a portable biofeedback device on improving sleep latency and other sleep variables such as nocturnal awake time and daytime functioning in persons with primary insomnia.
Detailed Description
There is evidence that when compared to normal controls, persons with insomnia exhibit increased cognitive and physiological arousal and higher overall metabolic rate during sleep, particularly at sleep onset. There is evidence that reducing this arousal may impact sleep latency and nocturnal awake time. Although relaxation treatments have been integrated into behavioral therapies, there are numerous barriers to their implementation in real world settings. The present study is designed to examine the effect of a portable biofeedback device designed to induce physiological relaxation as compared to an inactive sham control device condition in reducing sleep onset latency in persons with primary insomnia over a 4 week period at three separate research sites.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Insomnia
Keywords
Primary Insomnia, Chronic Insomnia, Biofeedback, Sleeplessness

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Single
Allocation
Randomized
Enrollment
132 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Portable Biofeedback
Primary Outcome Measure Information:
Title
Sleep latency at 4 week follow-up
Secondary Outcome Measure Information:
Title
wake time after sleep onset (WASO) at 4 week follow-up
Title
total awake time (SOL + WASO) at 4 week follow-up
Title
Shifting from moderate/severe insomnia to mild/no insomnia (Insomnia Severity Index)at 4 week follow-up
Title
Daytime functioning at 4 week follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Between the ages of 18-55 Met DSM-IV-TR criteria for Primary Insomnia as measured by the: Structured Interview for Sleep Disorders. Insomnia Severity Index (>14). Demonstrate Sleep Onset Latency of >=45 minutes on >= 3 nights per week greater than or equal to 6 days over the 2 week period. A mean SOL >= 30 minutes over the 2 week period between Screening and Baseline visits. Residential stability (1 year) and means to travel to appointments. Willing to provide the name and contact information of a secondary contact person. Off insomnia medications for at least one week prior to randomization and no more than 2 days of use during the first week of baseline. Ability to read in English. Provision of informed consent. Willing to comply with daily protocol. Ability to obtain a reading on the device. Exclusion Criteria: Been in more than 2 studies in the past 2 years Pregnant Terminal, progressive, and or unstable medical illness. Self-reported sleep disruptive medical disorder i. Chronic Pain, Fibromyalgia, Pheochromocytoma, Hyperthyroidism, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes. Current Axis I psychiatric disorder.(DSM-IV) i. Major Depressive Disorder, Depression, Generalized Anxiety Disorder, Attention Deficit Disorder, Post Traumatic Stress Disorder, Bipolar Disorder, Substance/Alcohol Use Disorders, Attention Deficit Hyperactivity Disorder, Schizophrenia/Psychotic Disorders, Delirium, Dementia, and/or Amnesic disorders, Panic Disorder w/ nocturnal panic attacks. Chronic alcohol use not diagnosed in criterion 6. i. Subjects unwilling to limit their alcohol intake to 2 standard drinks per day will be excluded. Raynaud's Disease Regularly taking anti-anxiety medications, beta blockers or other heart medications that regulate heartbeat, bronchodilators, respiratory stimulants, simulating antidepressants, sedating antidepressants, thyroid supplements, anti-psychotics, and/or steroids. Regularly taking antidepressants (Prozac, Zoloft, Paxil) and NOT on a fixed dosage for at least 1 month prior to entering the study. Regularly taking medication (prescribed or over the counter) for sleep difficulties (>3x week). Sleep medications include any substance for sleep not limited to but including FDA approved sleep medications, analgesics, antihistamines, decongestants, melatonin, L-trypotophan, and velarian. Unwilling to abstain from PRN sleep aides (prescribed or over the counter). Restless Leg Syndrome as assessed by structured interview. Symptoms of Sleep Apnea (BMI>32 and Epworth Sleepiness Scale >10) Own a negative air ionizer or have used one in the past to treat insomnia. If subject recognizes device during the ability to obtain a pulse rate wave reading on the device. More than 5 cups (8oz) of caffeinated drinks per day and/or unwilling to limit caffeine in-take to a maximum of 3 cups a day and not after 5pm during the intervention. Regular night-time shift work and rotating night-time shift work. Idiopathic Insomnia.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jack Edinger, Ph.D.
Organizational Affiliation
Duke Unversity Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Charles Morin, Ph.D.
Organizational Affiliation
University of Laval
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jack Edinger, Ph.D.
Phone
919-681-8392
Email
jack.edinger@duke.edu

12. IPD Sharing Statement

Citations:
PubMed Identifier
10617176
Citation
Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999 Dec 15;22(8):1134-56. doi: 10.1093/sleep/22.8.1134.
Results Reference
background
Links:
URL
http://www.aasmnet.org/
Description
Sleep website

Learn more about this trial

Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia

We'll reach out to this number within 24 hrs